terbinafine actavis
actavis group ptc ehf. - terbinafinas - kremas - 10 mg/g - terbinafine
meropenem actavis
actavis group ptc ehf. - meropenemas - milteliai injekciniam ar infuziniam tirpalui - 500 mg; 1 g - meropenem
bortezomib actavis
actavis group ptc ehf - bortezomibas - milteliai injekciniam tirpalui - 3,5 mg - bortezomib
levonorgestrel actavis
actavis group ptc ehf. - levonorgestrelis - tabletės - 750 µg - levonorgestrel
vancomycin actavis
actavis group ptc ehf - vankomicinas - milteliai infuzinio tirpalo koncentratui - 1000 mg; 500 mg - vancomycin
indapamide actavis
teva b.v. - indapamidas - pailginto atpalaidavimo tabletės - 1,5 mg - indapamide
quetiapine actavis
teva b.v. - kvetiapinas - plėvele dengtos tabletės - 200 mg; 150 mg; 100 mg; 25 mg; 300 mg - quetiapine
valsartan hct actavis
teva b.v. - valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 160 mg/25 mg; 80 mg/12,5 mg; 160 mg/12,5 mg - valsartan and diuretics
imipenem/cilastatin actavis
teva b.v. - imipenemas/cilastatinas - milteliai infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin
rapilysin
actavis group ptc ehf - reteplazė - miokardinis infarktas - antitromboziniai vaistai - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.